Last edition
News about Global Pharma
Philips and Masimo Renew Partnership to Accelerate Development of Next-Gen Monitoring Solutions
As part of the expanded partnership, Masimo’s advanced monitoring technologies — including SET pulse oximetry, Radius PPG, and a range of sensor innovations — will be integrated into Philips’ multi-parameter patient monitoring platforms.
Global Pharma | 13/09/2025 | By Dineshwori | 126
MIRA Secures Shareholder Approval to Acquire SKNY
The acquisition strengthens MIRA’s pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30 percent weight loss and nicotine craving reversal in preclinical studies.
Global Pharma | 13/09/2025 | By Dineshwori | 118
UK Risks Losing Global Life Sciences Edge as Pharma Investment Decline, ABPI Warns
The UK risks losing its world-leading position in life sciences as investment in pharmaceutical research and development continues to fall behind international competitors, according to a new report from the Association of the British Pharmaceutical Industry (ABPI).
Global Pharma | 12/09/2025 | By Dineshwori | 296
Otsuka Acquires CAN10 from Cantargia
The deal transfers Cantargia’s CAN10 antibody programme to Otsuka, with Cantargia securing an upfront payment of USD 33 Million.
Global Pharma | 12/09/2025 | By Dineshwori | 232
Bayer Launches Bayer Co.Lab AdVenture Platform in China
Bayer launches Co.Lab AdVenture to connect biotech startups with global VCs, accelerating early-stage innovation through its lifesciences incubator network.
Global Pharma | 11/09/2025 | By Dineshwori | 208
GBI Biomanufacturing has partnered with NanoRetinal to advance development and manufacturing of NAR-001, a novel nanoparticle therapy for Inherited Retinal Diseases.
Global Pharma | 10/09/2025 | By Mrinmoy Dey | 147
Wheeler Bio has partnered with Pharmefex Consulting to strengthen its ModularCMC platform by integrating regulatory and CMC expertise for accelerated IND submissions.
Global Pharma | 10/09/2025 | By Mrinmoy Dey | 121
AstraZeneca Rolls Out Anti-Complement Therapy for aHUS and PNH
AstraZeneca India launches Eculizumab (300 mg, 10 mg/ml), the first approved anti-complement therapy in India for the treatment of atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH), following CDSCO approval in January 2025 for import, sale and distribution.
Global Pharma | 09/09/2025 | By Dineshwori | 191
Made Scientific, Hemogenyx Partner to Advance CAR-T Cell Therapy for AML
Made Scientific and Hemogenyx Pharmaceuticals have announced a technology transfer and manufacturing partnership to advance HG-CT-1, an autologous CAR-T cell therapy for acute myeloid leukaemia (AML).
Global Pharma | 09/09/2025 | By Mrinmoy Dey | 144
Novartis to Acquire Tourmaline Bio for USD 48 per share
Novartis to acquire Tourmaline Bio in a USD 1.4 billion deal, gaining rights to pacibekitug—an anti-IL-6 antibody with potential in cardiovascular disease; transaction expected to close in Q4 2025.
Global Pharma | 09/09/2025 | By Dineshwori | 251
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy